Use of Adipose Septa Protein Modulators and Compositions Thereof
Methods of using adipose septa protein modulators to impart anti-aging benefits to the skin and/or improve skin conditions resulting from weakened or compromised adipose septa.
1 . A method for improving the appearance of skin affected by a skin irregularity resulting from changes in adipose septa comprising topically applying thereto an effective amount of at least one modulator of an adipose septa protein, in a cosmetically acceptable vehicle for a time sufficient to achieve an improvement in the appearance of said skin.
2 . The method according to claim 1 , wherein the modulator upregulates an adipose septa protein.
3 . The method according to claim 1 , wherein the modulator downregulates an adipose septa protein.
4 . The method according to claim 1 , wherein said skin irregularity is cellulite sagging facial skin, sagging neck skin, or scleroderma.
5 . The method according to claim 4 , wherein said skin irregularity is cellulite.
6 . The method according to claim 5 , wherein said achievement in the appearance of the skin is selected from the group consisting of:
(a) reduction in the appearance of cellulite lumpiness and/or unevenness;
(b) reduction in pitting appearance of cellulite upon squeezing;
(c) reduction in the extent of area affected by cellulite;
(d) prevention or delay in the recurrence of cellulite;
(e) improvement in collagen disposition; or
(f) improvement in adipocyte/fat tissue disposition;
7 . The method of claim 4 , wherein said skin irregularity is sagging of the facial skin.
8 . The method according to claim 8 , wherein said sagging of the facial skin is periorbital bulging.
9 . The method of claim 7 , wherein said achievement in the appearance of the skin is selected from the group consisting of:
(a) improvement in adipocyte/fat tissue disposition;
(b) reduction in sagging of the facial skin; or
(c) reduction in the extent of the area affected by sagging.
10 . The method of claim 1 , wherein the modulator comprises palmitoyl lysyl aminovaleroyl lysine, an extract of Amorphophallus campanulantus , an extract of Mademia nobilis , an extract of Erythrina indica , an extract of Ixora chinensis , an extract of Operculina turpethum , an extract of Portulaca oleracea , an extract of Tiliacora triandra , an extract of Melicope , an extract of Butea frodosa , or combination thereof.
11 . The method of claim 10 , wherein the modulator is not an extract of Tiliacora triandra or Melicope.
12 . The method of claim 1 , wherein the adipose septa protein comprises asporin, biglycan, decorin, dermatopontin, fibromodulin, fibronectin, galectin-1, laminin beta 2, lumican, MAGP-4, mimecan (osteoglycin), nidogen-1, nidogen-2, or prolargin.
13 . The method of claim 1 , wherein the modulator is in combination with at least one other anti-lipid agent.
14 . The method according to claim 13 , wherein said at least one other anti-lipid agent comprises a carnitine palmitoyl transferase-1 stimulator.
15 . The method of claim 1 , wherein the modulator is in combination with at least one anti-cellulite agent.
16 . The method of claim 15 , wherein the at least one anti-cellulite agent is selected from the group consisting of a phophodiesterase inhibitor, an adenylate cyclase activator, a lipolysis stimulator, a beta-adrenergic receptor agonist, an alpha-2-adreneric receptor antagonist, perilla oil, carnitine, creatine, or combination thereof.
17 . The method according to claim 1 , wherein said modulator is in combination with at least one collagen and/or elastin stimulator.
18 . The method according to claim 1 , wherein said modulator is in combination with a retinoid.
19 . The method of claim 1 , wherein an effective amount of the modulator is about 0.001% to about 25% by weight.
20 . A method for screening active agents useful for improving the aesthetic appearance of skin comprising assaying candidate substances for ability to modify adipose septa protein expression.
21 . A method of treating the skin comprising topically applying to an area of the skin in need thereof an effective amount of an active agent that modulates adipose septa protein expression, wherein the ability of said active agent to modulate adipose septa protein expression has been determined by an assay which measures the level of mRNA encoding adipose septa protein in a cell that has been contacted with said active agent.